Sage Journals: Discover world-class research

Abstract

We present the case of a 36-year-old woman affected with Fabry disease (FD), with neuroradiologic and laboratory tests suggestive of a coexistent inflammatory demyelinating disease. Since the age of 23, she presented recurrent neurologic deficits, such as right limb paresthesias, diplopia, and right leg weakness. Magnetic resonance imaging revealed multiple demyelinating lesions in periventricular areas, corpus callosum, and spinal cord. Cerebrospinal fluid analysis showed the presence of oligoclonal bands, while visual-evoked potentials were delayed with preserved morphology. FD is usually considered as a differential diagnosis of multiple sclerosis, but we think that the best explanation of all pathological features in this case is the coexistence of the two diseases.

Keywords

evoked potentials Fabry disease magnetic resonance imaging multiple sclerosis oligoclonal bands white matter lesions

Get full access to this article

View all access options for this article.

References

1 Desnick RJ Brady R Barranger J . Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138: 338–346.

2 Deegan PB Baehner AF Barba Romero MA Hughes DA Kampmann C Beck M . European FOS Investigators. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006; 43: 347–352.

3 Fellgiebel A Müller MJ Ginsberg L . CNS manifestations of Fabry's disease. Lancet Neurol 2006; 5: 791–795.

4 Ginsberg L Manara R Valentine AR Kendall B Burlina AP . Magnetic resonance imaging changing in Fabry disease. Acta Paediatr Suppl 2006; 451: 57–62.

5 Moore DF Altarescu G Barker WC Patronas NJ Herscovitch P Schiffmann R . White matter lesions in Fabry disease occur in ‘prior’ selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003; 62: 231–240.

6 Fellgiebel A Müller MJ Mazanek M Baron K Beck M Stoeter P . White matter lesion severity in male and female patients with Fabry disease. Neurology 2005; 65: 600–602.

7 Eng CM Guffon N Wilcox WR . International Collaborative Fabry Disease Group. Safety and efficacy of recombinant human α-galactosidase A-replacement therapy in Fabry’s disease. N Engl J Med 2001; 345: 9–16.

8 Rahman P Gladman DD Wither J Silver MD . Coexistence of Fabry’s disease and systemic lupus erythematosus. Clin Exp Rheumatol 1998; 16: 475–478.

9 Arias N Barbado FJ Pérez Martìn G Pérez de Ayala C Casal V Vázquez JJ . Enfermidad de Fabry asociada a artritis reumatoide. Una encrucijada multisistémica. Ann Med Int (Madrid) 2003; 20: 28–30.

10.

10 Tumer L Ezgu FS Hasanoglu A Dalgıç B Bakkaloğlu SA Memiş L . The co-existence of Fabry and celiac disease: a case report. Pediatr Nephrol 2004; 19: 679–681.

11.

11 Callegaro D Kaimen-Maciel L . Fabry disease as a differential diagnosis of multiple sclerosis. Int MS J 2006; 13: 27–30.

12.

12 Saip S Uluduz D Erkol G . Fabry disease mimicking multiple sclerosis. Clin Neurol Neurosurg 2007; 109: 361–363.

13.

13 Loeb H Jonnieaux G Tondeur M . Etude clinique, biochimique et ultrastructurelle de la maladie de Fabry chez l’enfant. Helv Paediatr Acta 1968; 3: 269–286.

14.

14 Rosemann E Kobrin I Cohen T . Kidney involvement en SLE and Fabry’s disease. Nephron 1983; 34: 180–184.

15.

15 Fisher EG Moore MJ Lager DJ . Fabry disease: a morphologic study of 11 cases. Mod Pathol 2006; 19: 1295–1301.

A case of Fabry disease with central nervous system (CNS) demyelinating lesions: a double trouble?

Abstract

Keywords

Get full access to this article

References